AKT1 and prostate cancer: For example, Q enhanced DOX efficacy against DOX-resistant prostate cancer cells (PC-3/R) by downregulating the expression of the c-met and phosphoinositide 3-kinases/protein kinase B (AKT) pathway in vitro [21].